{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:20:55Z","timestamp":1793013655966,"version":"4.5.0"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T00:00:00Z","timestamp":1559692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T00:00:00Z","timestamp":1559692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Ewopharma International"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s12325-019-00995-6","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T15:02:32Z","timestamp":1559746952000},"page":"1878-1905","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases"],"prefix":"10.1007","volume":"36","author":[{"given":"Jiri","family":"Sliva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6895-3105","authenticated-orcid":false,"given":"Chrysoula N.","family":"Pantzartzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Votava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,5]]},"reference":[{"key":"995_CR1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/978-1-4615-9358-4_25","volume-title":"Immunomodulation","author":"J Wybran","year":"1984","unstructured":"Wybran J, Appelboom T. Isoprinosine (inosiplex): immunological and clinical effects. Immunomodulation. Boston, MA: Springer; 1984. p. 363\u201374."},{"key":"995_CR2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/978-3-0346-0136-8_22","volume-title":"Principles of immunopharmacology","author":"KN Masihi","year":"2011","unstructured":"Masihi KN. C7 Anti-infective activity of immunomodulators. Principles of immunopharmacology. Basel: Birkh\u00e4user; 2011. p. 411\u201335."},{"issue":"6","key":"995_CR3","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/1346-8138.12845","volume":"42","author":"Y You","year":"2015","unstructured":"You Y, Wang L, Li Y, Wang Q, Cao S, Tu Y, et al. Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients. J Dermatol. 2015;42(6):596\u2013601. https:\/\/doi.org\/10.1111\/1346-8138.12845 .","journal-title":"J Dermatol"},{"key":"995_CR4","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1136\/ard.49.5.293","volume":"49","author":"M Brzeski","year":"1990","unstructured":"Brzeski M, Madhok R, Hunter JA, Capel HA. Randomised, double blind, placebo controlled trial of inosine pranobex in rheumatoid arthritis. Ann Rheum Dis. 1990;49:293\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"995_CR5","first-page":"637","volume":"73","author":"A Majewska","year":"2016","unstructured":"Majewska A, Lasek W, Janyst M, Mlynarczyk G. In vitro inhibition of HHV-1 replication by inosine pranobex and interferon-\u03b1. Acta Pol Pharm. 2016;73(3):637\u201344.","journal-title":"Acta Pol Pharm"},{"issue":"2","key":"995_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2478\/jvetres-2018-0030","volume":"62","author":"S Tobolska","year":"2018","unstructured":"Tobolska S, Terpilowska S, Jaroszewski J, Siwicki AK. Genotoxicity and mutagenicity of inosine pranobex. J Vet Res. 2018;62(2):207\u201313. https:\/\/doi.org\/10.2478\/jvetres-2018-0030 .","journal-title":"J Vet Res"},{"issue":"2","key":"995_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2478\/jvetres-2018-0031","volume":"62","author":"S Tob\u00f3lska","year":"2018","unstructured":"Tob\u00f3lska S, Terpi\u0142owska S, Jaroszewski J, Siwicki AK. Influence of inosine pranobex on cell viability in normal fibroblasts and liver cancer cells. J Vet Res. 2018;62(2):215\u201320. https:\/\/doi.org\/10.2478\/jvetres-2018-0031 .","journal-title":"J Vet Res"},{"key":"995_CR8","doi-asserted-by":"crossref","unstructured":"Hadden J, Wybran J, editors. Immunopotentiators II Isoprinosine, NPT 15392 and Azimexone: modulators of lymphocyte and macrophage development and function. Advances in Immunopharmacology: Proceedings of the First International Conference on Immunopharmacology; 1981: Elsevier.","DOI":"10.1016\/B978-0-08-026384-7.50056-2"},{"issue":"4","key":"995_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1089\/jir.2009.0057","volume":"30","author":"M Petrova","year":"2010","unstructured":"Petrova M, Jelev D, Ivanova A, Krastev Z. Isoprinosine affects serum cytokine levels in healthy adults. J Interferon Cytokine Res. 2010;30(4):223\u20138. https:\/\/doi.org\/10.1089\/jir.2009.0057 .","journal-title":"J Interferon Cytokine Res"},{"issue":"2","key":"995_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1515\/acph-2015-0015","volume":"65","author":"W Lasek","year":"2015","unstructured":"Lasek W, Janyst M, Wolny R, Zapala L, Bocian K, Drela N. Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes. Acta Pharm. 2015;65(2):171\u201380. https:\/\/doi.org\/10.1515\/acph-2015-0015 .","journal-title":"Acta Pharm"},{"issue":"7","key":"995_CR11","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/0192-0561(91)90055-C","volume":"13","author":"S Milano","year":"1991","unstructured":"Milano S, Dieli M, Millott S, Miceli MD, Maltese E, Cillari E. Effect of isoprinosine on IL-2, IFN-gamma and IL-4 production in vivo and in vitro. Int J Immunopharmacol. 1991;13(7):1013\u20138.","journal-title":"Int J Immunopharmacol"},{"issue":"2","key":"995_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0192-0561(85)90027-X","volume":"7","author":"KY Tsang","year":"1985","unstructured":"Tsang KY, Pan JF, Swanger DL, Fudenberg HH. In vitro restoration of immune responses in aging humans by isoprinosine. Int J Immunopharmacol. 1985;7(2):199\u2013206. https:\/\/doi.org\/10.1016\/0192-0561(85)90027-X .","journal-title":"Int J Immunopharmacol"},{"issue":"6","key":"995_CR13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/0192-0561(83)90041-3","volume":"5","author":"KY Tsang","year":"1983","unstructured":"Tsang KY, Fudenberg HH, Pan JF, Gnagy MJ, Bristow CB. An in vitro study on the effects of isoprinosine on immune responses in cancer patients. Int J Immunopharmacol. 1983;5(6):481\u201390.","journal-title":"Int J Immunopharmacol"},{"issue":"5","key":"995_CR14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.cytogfr.2010.09.002","volume":"21","author":"R Sabat","year":"2010","unstructured":"Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010;21(5):331\u201344. https:\/\/doi.org\/10.1016\/j.cytogfr.2010.09.002 .","journal-title":"Cytokine Growth Factor Rev"},{"key":"995_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.intimp.2016.11.023","volume":"42","author":"RS Ahmed","year":"2017","unstructured":"Ahmed RS, Newman AS, O\u2019Daly J, Duffy S, Grafton G, Brady CA, et al. Inosine acedoben dimepranol promotes an early and sustained increase in the natural killer cell component of circulating lymphocytes: a clinical trial supporting anti-viral indications. Int Immunopharmacol. 2017;42:108\u201314. https:\/\/doi.org\/10.1016\/j.intimp.2016.11.023 .","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"995_CR16","first-page":"577","volume":"2","author":"C Balestrino","year":"1983","unstructured":"Balestrino C, Montesoro E, Nocera A, Ferrarini M, Hoffman T. Augmentation of human peripheral blood natural killer activity by methisoprinol. J Biol Response Modif. 1983;2(6):577\u201385.","journal-title":"J Biol Response Modif"},{"issue":"2","key":"995_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1300\/J092v11n02_06","volume":"11","author":"F Diaz-Mitoma","year":"2003","unstructured":"Diaz-Mitoma F, Turgonyi E, Kumar A, Lim W, Larocque L, Hyde BM. Clinical improvement in chronic fatigue syndrome is associated with enhanced natural killer cell-mediated cytotoxicity: the results of a pilot study with Isoprinosine\u00ae. J Chronic Fatigue Syndr. 2003;11(2):71\u201395.","journal-title":"J Chronic Fatigue Syndr"},{"issue":"4","key":"995_CR18","first-page":"155","volume":"24","author":"JG Bekesi","year":"1987","unstructured":"Bekesi JG, Tsang PH, Wallace JI, Roboz JP. Immunorestorative properties of isoprinosine in the treatment of patients at high risk of developing ARC or AIDS. J Clin Lab Immunol. 1987;24(4):155\u201361.","journal-title":"J Clin Lab Immunol"},{"issue":"4","key":"995_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0192-0561(84)90048-1","volume":"6","author":"P Hersey","year":"1984","unstructured":"Hersey P, Edwards A. Effect of isoprinosine on natural killer cell activity of blood mononuclear cells in vitro and in vivo. Int J Immunopharmacol. 1984;6(4):315\u201320.","journal-title":"Int J Immunopharmacol"},{"issue":"3","key":"995_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0192-0561(83)90055-3","volume":"5","author":"H Ohnishi","year":"1983","unstructured":"Ohnishi H, Kosuzume H, Inaba H, Ohkura M, Shimada S, Suzuki Y. The immunomodulatory action of inosiplex in relation to its effects in experimental viral infections. Int J Immunopharmacol. 1983;5(3):181\u201396.","journal-title":"Int J Immunopharmacol"},{"issue":"4","key":"995_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/0192-0561(82)90399-X","volume":"4","author":"C De Simone","year":"1982","unstructured":"De Simone C, Ricca D, Sorice F. In vitro influence of methisoprinol on human eosinophils. Int J Immunopharmacol. 1982;4(4):369.","journal-title":"Int J Immunopharmacol"},{"issue":"1","key":"995_CR22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1128\/IAI.38.1.243-250.1982","volume":"38","author":"H Ohnishi","year":"1982","unstructured":"Ohnishi H, Kosuzume H, Inaba H, Okura M, Morita Y, Mochizuki H, et al. Mechanism of host defense suppression induced by viral infection: mode of action of inosiplex as an antiviral agent. Infect Immun. 1982;38(1):243\u201350.","journal-title":"Infect Immun"},{"issue":"3","key":"995_CR23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/08923977909026379","volume":"1","author":"G Renoux","year":"1979","unstructured":"Renoux G, Renoux M, Guillaumin J-M. Isoprinosine as an immunopotentiator. J Immunopharmacol. 1979;1(3):337\u201356.","journal-title":"J Immunopharmacol"},{"issue":"2","key":"995_CR24","first-page":"109","volume":"10","author":"A Morin","year":"1982","unstructured":"Morin A, Ballet JJ. A recent overview on in vitro and in vivo immunological activities of methisoprinol. Allergol Immunopathol (Madr). 1982;10(2):109\u201314.","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"9","key":"995_CR25","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1139\/m72-224","volume":"18","author":"P Gordon","year":"1972","unstructured":"Gordon P, Brown ER. The antiviral activity of Isoprinosine. Can J Microbiol. 1972;18(9):1463\u201370. https:\/\/doi.org\/10.1139\/m72-224 .","journal-title":"Can J Microbiol"},{"key":"995_CR26","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-1-4613-1901-6_32","volume-title":"Antibiosis and host immunity","author":"C De Simone","year":"1987","unstructured":"De Simone C, Prohost JW. Prohost modulation of immunity by isoprinosine and NPT 15392. Antibiosis and host immunity. Boston, MA: Springer; 1987. p. 279\u201390."},{"issue":"2","key":"995_CR27","first-page":"219","volume":"29","author":"R Linhares","year":"1996","unstructured":"Linhares R, Rebello M, Nozawa C. Effect of isoprinosine on rotavirus replication in vitro. Braz J Med Biol Res. 1996;29(2):219\u201322.","journal-title":"Braz J Med Biol Res"},{"issue":"1","key":"995_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/nar\/gky1163","volume":"47","author":"K Licht","year":"2019","unstructured":"Licht K, Hartl M, Amman F, Anrather D, Janisiw MP, Jantsch MF. Inosine induces context-dependent recoding and translational stalling. Nucleic Acids Res. 2019;47(1):3\u201314. https:\/\/doi.org\/10.1093\/nar\/gky1163 .","journal-title":"Nucleic Acids Res"},{"key":"995_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1146\/annurev.pa.24.040184.001051","volume":"24","author":"HH Fudenberg","year":"1984","unstructured":"Fudenberg HH, Whitten HD. Immunostimulation: synthetic and biological modulators of immunity. Annu Rev Pharmacol Toxicol. 1984;24:147\u201374. https:\/\/doi.org\/10.1146\/annurev.pa.24.040184.001051 .","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"995_CR30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/978-1-4615-9358-4_23","volume-title":"Immunomodulation","author":"T Ginsberg","year":"1984","unstructured":"Ginsberg T, Hadden J. Immunopharmacology of methisoprinol. Immunomodulation. Boston, MA: Springer; 1984. p. 331\u201348."},{"issue":"5","key":"995_CR31","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/00003495-198632050-00001","volume":"32","author":"DM Campoli-Richards","year":"1986","unstructured":"Campoli-Richards DM, Sorkin EM, Heel RC. Inosine pranobex. Drugs. 1986;32(5):383\u2013424.","journal-title":"Drugs"},{"issue":"11","key":"995_CR32","first-page":"1963","volume":"62","author":"LN Simon","year":"1978","unstructured":"Simon LN, Glasky AJ. Isoprinosine: an overview. Cancer Treat Rep. 1978;62(11):1963\u20139.","journal-title":"Cancer Treat Rep"},{"issue":"2","key":"995_CR33","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/0090-1229(87)90031-6","volume":"45","author":"PH Tsang","year":"1987","unstructured":"Tsang PH, Sei Y, Bekesi JG. Isoprinosine-induced modulation of T-helper-cell subsets and antigen-presenting monocytes (Leu M3\u2009+\u2009Ia\u2009+) resulted in improvement of T- and B-lymphocyte functions, in vitro in ARC and AIDS patients. Clin Immunol Immunopathol. 1987;45(2):166\u201376.","journal-title":"Clin Immunol Immunopathol"},{"issue":"9 Supplement","key":"995_CR34","first-page":"4671s","volume":"45","author":"A Pompidou","year":"1985","unstructured":"Pompidou A, Delsaux M, Telvi L, Mace B, Coutance F, Falkenrodt A, et al. Isoprinosine and imuthiol, two potentially active compounds in patients with AIDS-related complex symptoms. Cancer Res. 1985;45(9 Supplement):4671s\u20133s.","journal-title":"Cancer Res"},{"issue":"1","key":"995_CR35","first-page":"25","volume":"74","author":"E Cillari","year":"1991","unstructured":"Cillari E, Dieli M, Lo Campo P, Sireci G, Caffarelli A, Maltese E, et al. Protective effect of isoprinosine in genetically susceptible BALB\/c mice infected with Leishmania major. Immunology. 1991;74(1):25\u201330.","journal-title":"Immunology"},{"issue":"1","key":"995_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4149\/av_2017_01_32","volume":"61","author":"O Jan\u00ed\u010dkov\u00e1","year":"2017","unstructured":"Jan\u00ed\u010dkov\u00e1 O, An\u010dicov\u00e1 L, Briestenska K, Mistrikova J. The effect of Isoprinosine treatment on persistent infection of Balb\/c mice infected with murine gammaherpesvirus 68. Acta Virol. 2017;61(1):32\u20138.","journal-title":"Acta Virol"},{"issue":"1","key":"995_CR37","first-page":"80","volume":"2","author":"Z Krastev","year":"2015","unstructured":"Krastev Z, Jelev D, Ivanova R. Isoprinosine induces a rapid lympho-mononuclear response in adult participants. Med Inf. 2015;2(1):80\u20135.","journal-title":"Med Inf"},{"key":"995_CR38","first-page":"41A","volume":"27","author":"L Corey","year":"1979","unstructured":"Corey L, Chiang W, Reeves W, Stamm W, Brewer L, Holmes K. Effect of isoprinosine on the cellular immune response in initial genital herpes virus infection. Clin Res. 1979;27:41A.","journal-title":"Clin Res"},{"issue":"2","key":"995_CR39","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S0190-9622(84)70153-8","volume":"11","author":"GM Galbraith","year":"1984","unstructured":"Galbraith GM, Thiers BH, Fudenberg HH. An open-label trial of immunomodulation therapy with inosiplex (Isoprinosine) in patients with alopecia totalis and cell-mediated immunodeficiency. J Am Acad Dermatol. 1984;11(2):224\u201330.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"995_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S0190-9622(85)70013-8","volume":"12","author":"M Lowy","year":"1985","unstructured":"Lowy M, Ledoux-Corbusier M, Achten G, Wybran J. Clinical and immunologic response to Isoprinosine in alopecia areata and alopecia universalis: association with autoantibodies. J Am Acad Dermatol. 1985;12(1):78\u201384.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"995_CR41","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/0192-0561(85)90232-2","volume":"7","author":"J Wybran","year":"1985","unstructured":"Wybran J, Schanden\u00e9 L. Isoprinosine in aphthous stomatitis: clinical improvement associated with enhancement of IL2 production. Int J Immunopharmacol. 1985;7(3):318.","journal-title":"Int J Immunopharmacol"},{"issue":"16\u201318","key":"995_CR42","first-page":"347","volume":"45","author":"B Dabrowska-Bernstein","year":"1990","unstructured":"Dabrowska-Bernstein B, Stasiak A, Dabrowski M, Pawinska A, Cianciara J, Loch T, et al. Evaluation of the treatment of chronic active hepatitis (HBsAg\u2009+) with isoprinosine II Immunological studies. Pol Tyg Lek. 1990;45(16\u201318):347\u201351.","journal-title":"Pol Tyg Lek"},{"issue":"6","key":"995_CR43","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3109\/00365549009027115","volume":"22","author":"J Cianciara","year":"1990","unstructured":"Cianciara J, Laskus T, Gabinska E, Loch T. Isoprinosine in the treatment of chronic active hepatitis type B. Scand J Infect Dis. 1990;22(6):645\u20138.","journal-title":"Scand J Infect Dis"},{"issue":"12","key":"995_CR44","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1128\/AAC.32.12.1784","volume":"32","author":"RF Schinazi","year":"1988","unstructured":"Schinazi RF, Cannon DL, Arnold BH, Martino-Saltzman D. Combinations of isoprinosine and 3\u2032-azido-3\u2032-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1988;32(12):1784\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"995_CR45","doi-asserted-by":"publisher","first-page":"395","DOI":"10.5114\/ceji.2015.56960","volume":"40","author":"A Majewska","year":"2015","unstructured":"Majewska A, Lasek W, Janyst M, M\u0142ynarczyk G. Inhibition of adenovirus multiplication by inosine pranobex and interferon \u03b1 in vitro. Cent Eur J Immunol. 2015;40(4):395\u20139. https:\/\/doi.org\/10.5114\/ceji.2015.56960 .","journal-title":"Cent Eur J Immunol"},{"issue":"2","key":"995_CR46","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1128\/AAC.00615-10","volume":"55","author":"J Piret","year":"2011","unstructured":"Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother. 2011;55(2):459\u201372. https:\/\/doi.org\/10.1128\/AAC.00615-10 .","journal-title":"Antimicrob Agents Chemother"},{"issue":"9605","key":"995_CR47","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/s0140-6736(07)61908-4","volume":"370","author":"R Gupta","year":"2007","unstructured":"Gupta R, Warren T, Wald A. Genital herpes. Lancet. 2007;370(9605):2127\u201337. https:\/\/doi.org\/10.1016\/s0140-6736(07)61908-4 .","journal-title":"Lancet"},{"issue":"10","key":"995_CR48","doi-asserted-by":"publisher","first-page":"e0140765","DOI":"10.1371\/journal.pone.0140765","volume":"10","author":"KJ Looker","year":"2015","unstructured":"Looker KJ, Magaret AS, May MT, Turner KME, Vickerman P, Gottlieb SL, et al. Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. PLoS ONE. 2015;10(10):e0140765. https:\/\/doi.org\/10.1371\/journal.pone.0140765 .","journal-title":"PLoS ONE"},{"issue":"1","key":"995_CR49","doi-asserted-by":"publisher","first-page":"e114989","DOI":"10.1371\/journal.pone.0114989","volume":"10","author":"KJ Looker","year":"2015","unstructured":"Looker KJ, Magaret AS, Turner KME, Vickerman P, Gottlieb SL, Newman LM. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS ONE. 2015;10(1):e114989. https:\/\/doi.org\/10.1371\/journal.pone.0114989 .","journal-title":"PLoS ONE"},{"issue":"3","key":"995_CR50","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1053\/j.semperi.2018.02.004","volume":"42","author":"SG Pinninti","year":"2018","unstructured":"Pinninti SG, Kimberlin DW. Neonatal herpes simplex virus infections. Semin Perinatol. 2018;42(3):168\u201375. https:\/\/doi.org\/10.1053\/j.semperi.2018.02.004 .","journal-title":"Semin Perinatol"},{"key":"995_CR51","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.14166","author":"M Mekki","year":"2019","unstructured":"Mekki M, Eley B, Hardie D. Wilmshurst JM Subacute sclerosing panencephalitis: clinical phenotype, epidemiology, and preventive interventions. Dev Med Child Neurol. 2019. https:\/\/doi.org\/10.1111\/dmcn.14166 .","journal-title":"Dev Med Child Neurol"},{"issue":"10","key":"995_CR52","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/j.1469-8749.2010.03717.x","volume":"52","author":"J Gutierrez","year":"2010","unstructured":"Gutierrez J, Issacson RS, Koppel BS. Subacute sclerosing panencephalitis: an update. Dev Med Child Neurol. 2010;52(10):901\u20137. https:\/\/doi.org\/10.1111\/j.1469-8749.2010.03717.x .","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"995_CR53","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1586\/ern.12.21","volume":"12","author":"B Tatli","year":"2012","unstructured":"Tatli B, Ekici B, Ozmen M. Current therapies and future perspectives in subacute sclerosing panencephalitis. Expert Rev Neurother. 2012;12(4):485\u201392. https:\/\/doi.org\/10.1586\/ern.12.21 .","journal-title":"Expert Rev Neurother"},{"issue":"9","key":"995_CR54","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.braindev.2011.12.008","volume":"34","author":"N Gadoth","year":"2012","unstructured":"Gadoth N. Subacute sclerosing panencephalitis (SSPE) the story of a vanishing disease. Brain Dev. 2012;34(9):705\u201311. https:\/\/doi.org\/10.1016\/j.braindev.2011.12.008 .","journal-title":"Brain Dev"},{"issue":"4","key":"995_CR55","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410130416","volume":"13","author":"MJ Noetzel","year":"1983","unstructured":"Noetzel MJ, Dodson WE. Progressive CT abnormalities despite clinical improvement in SSPE treated with inosiplex. Ann Neurol. 1983;13(4):457\u201360. https:\/\/doi.org\/10.1002\/ana.410130416 .","journal-title":"Ann Neurol"},{"issue":"9","key":"995_CR56","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1177\/088307380201700911","volume":"17","author":"T Solomon","year":"2002","unstructured":"Solomon T, Hart CA, Vinjamuri S, Beeching NJ, Malucci C, Humphrey P. Treatment of subacute sclerosing panencephalitis with interferon-alpha, ribavirin, and inosiplex. J Child Neurol. 2002;17(9):703\u20135. https:\/\/doi.org\/10.1177\/088307380201700911 .","journal-title":"J Child Neurol"},{"issue":"6","key":"995_CR57","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1212\/WNL.29.6.763","volume":"29","author":"PR Huttenlocher","year":"1979","unstructured":"Huttenlocher PR, Mattson RH. Isoprinosine in subacute sclerosing panencephalitis. Neurology. 1979;29(6):763\u201371.","journal-title":"Neurology"},{"issue":"6","key":"995_CR58","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/archneur.1979.00500420084012","volume":"36","author":"R Silverberg","year":"1979","unstructured":"Silverberg R, Brenner T, Abramsky O. Inosiplex in the Treatment of Subacute Sclerosing Panencephalitis. Arch Neurol. 1979;36(6):374\u20135. https:\/\/doi.org\/10.1001\/archneur.1979.00500420084012 .","journal-title":"Arch Neurol"},{"issue":"2","key":"995_CR59","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/S0022-3476(82)80143-1","volume":"101","author":"RH DuRant","year":"1982","unstructured":"DuRant RH, Dyken PR, Swift AV. The influence of inosiplex treatment on the neurological disability of patients with subacute sclerosing panencephalitis. J Pediatr. 1982;101(2):288\u201393.","journal-title":"J Pediatr"},{"issue":"2","key":"995_CR60","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ana.410070216","volume":"7","author":"FS Haddad","year":"1980","unstructured":"Haddad FS, Risk WS. Isoprinosine treatment in 18 patients with subacute sclerosing panencephalitis: a controlled study. Ann Neurol. 1980;7(2):185\u20138. https:\/\/doi.org\/10.1002\/ana.410070216 .","journal-title":"Ann Neurol"},{"issue":"8280","key":"995_CR61","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S0140-6736(82)92097-9","volume":"319","author":"C Jones","year":"1982","unstructured":"Jones C, Huttenlocher P, Dyken P, Jabbour JT, Maxwell K. Inosiplex therapy in subacute sclerosing panencephalitis: a multicentre, non-randomised study in 98 patients. Lancet. 1982;319(8280):1034\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(82)92097-9 .","journal-title":"Lancet"},{"issue":"11","key":"995_CR62","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1016\/j.clinthera.2004.11.002","volume":"26","author":"B Anlar","year":"2004","unstructured":"Anlar B, Aydin OF, Guven A, Sonmez FM, Kose G, Herguner O. Retrospective evaluation of interferon-beta treatment in subacute sclerosing panencephalitis. Clin Ther. 2004;26(11):1890\u20134. https:\/\/doi.org\/10.1016\/j.clinthera.2004.11.002 .","journal-title":"Clin Ther"},{"issue":"11","key":"995_CR63","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1177\/088307389801301106","volume":"13","author":"B Anlar","year":"1998","unstructured":"Anlar B, Yalaz K, Kose G, Saygi S. Beta-interferon plus inosiplex in the treatment of subacute sclerosing panencephalitis. J Child Neurol. 1998;13(11):557\u20139. https:\/\/doi.org\/10.1177\/088307389801301106 .","journal-title":"J Child Neurol"},{"issue":"3","key":"995_CR64","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S0387-7604(87)80044-X","volume":"9","author":"Y Fukuyama","year":"1987","unstructured":"Fukuyama Y, Nihei K, Matsumoto S, Ebina T, Kamoshita S, Sato T, et al. Clinical effects of MND-19 (Inosiplex) on subacute sclerosing panencephalitis\u2014a multi-institutional collaborative study\u2014the Inosiplex-SSPE Research Committee. Brain Dev. 1987;9(3):270\u201382.","journal-title":"Brain Dev"},{"issue":"2","key":"995_CR65","first-page":"27","volume":"2","author":"A Nasirian","year":"2008","unstructured":"Nasirian A, Ashrafi M, Nasrabady SE. Use of A-interferon, amantadin and isoprinosine in subacute sclerosing panencephalitis (sspe): comparing the effectiveness. Iran J Child Neurol. 2008;2(2):27\u201332.","journal-title":"Iran J Child Neurol"},{"issue":"5","key":"995_CR66","first-page":"626","volume":"25","author":"W Sobczyk","year":"1991","unstructured":"Sobczyk W, Kulczycki J, Pi\u0142kowska E, Iwi\u0144ska B, Milewska D, Szmigielski S. Comparison of the results of the treatment of patients with SSPE using various immunomodulating preparations. Neurol Neurochir Pol. 1991;25(5):626\u201333.","journal-title":"Neurol Neurochir Pol"},{"issue":"2","key":"995_CR67","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/08830738030180020701","volume":"18","author":"\u00d6F Aydin","year":"2003","unstructured":"Aydin \u00d6F, \u015eenbil N, Kuyucu N, G\u00fcrer YKY. Combined treatment with subcutaneous interferon-\u03b1, oral isoprinosine, and lamivudine for subacute sclerosing panencephalitis. J Child Neurol. 2003;18(2):104\u20138. https:\/\/doi.org\/10.1177\/08830738030180020701 .","journal-title":"J Child Neurol"},{"issue":"6","key":"995_CR68","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1055\/s-0035-1564618","volume":"46","author":"M H\u00e4usler","year":"2015","unstructured":"H\u00e4usler M, Aksoy A, Alber M, Altunbasak S, Angay A, Arsene OT, et al. A multinational survey on actual diagnostics and treatment of subacute sclerosing panencephalitis. Neuropediatrics. 2015;46(6):377\u201384.","journal-title":"Neuropediatrics"},{"issue":"8","key":"995_CR69","first-page":"557","volume":"24","author":"A Rafique","year":"2014","unstructured":"Rafique A, Amjad N, Chand P, Zaidi SSZ, Rana MS, Ahmed K, et al. Subacute sclerosing panencephalitis: clinical and demographic characteristics. J Coll Physicians Surg Pak. 2014;24(8):557\u201360.","journal-title":"J Coll Physicians Surg Pak"},{"key":"995_CR70","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1136\/sti.62.5.352","volume":"62","author":"CK Mohanty","year":"1986","unstructured":"Mohanty CK, Scott SC. Immunotherapy of genital warts with inosine pranobex (Imunovir): preliminary study. Genitourin Med. 1986;62:352\u20135. https:\/\/doi.org\/10.1136\/sti.62.5.352 .","journal-title":"Genitourin Med"},{"issue":"11","key":"995_CR71","first-page":"681","volume":"79","author":"G Sadoul","year":"1984","unstructured":"Sadoul G, Beuret T. Treatment of cervical and vulvar condylomata by CO2 laser also with a immunostimulant. Rev Fr Gynecol Obstet. 1984;79(11):681\u20134.","journal-title":"Rev Fr Gynecol Obstet"},{"issue":"6","key":"995_CR72","first-page":"383","volume":"64","author":"J Davidson-Parker","year":"1988","unstructured":"Davidson-Parker J, Dinsmore W, Khan MH, Hicks DA, Morris CA, Morris DF. Immunotherapy of genital warts with inosine pranobex and conventional treatment: double blind placebo controlled study. Genitourin Med. 1988;64(6):383\u20136.","journal-title":"Genitourin Med"},{"issue":"4","key":"995_CR73","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1258\/0956462961917960","volume":"7","author":"SK Tay","year":"1996","unstructured":"Tay SK. Efficacy of inosine pranobex oral therapy in subclinical human papillomavirus infection of the vulva: a randomized double-blinded placebo controlled study. Int J STD AIDS. 1996;7(4):276\u201380. https:\/\/doi.org\/10.1258\/0956462961917960 .","journal-title":"Int J STD AIDS"},{"issue":"5","key":"995_CR74","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2340\/0001555576404404","volume":"76","author":"C Sand-Petersen","year":"1996","unstructured":"Sand-Petersen C, Weismann K. Isoprenosine improves symptoms in young females with chronic vulvodynia. Acta Derm Venereol. 1996;76(5):404.","journal-title":"Acta Derm Venereol"},{"key":"995_CR75","first-page":"27","volume":"6","author":"AG Kedrova","year":"2006","unstructured":"Kedrova AG, Podisov YI, Kuznetsov VV, Bryugzin VV, Kozachenko VP, Nikogosyan SO. Role of antiviral therapy in the complex treatment of patients with epithelial dysplasias and preinvasive cancer of the cervix uteri. Akush Ginekol. 2006;6:27\u201330.","journal-title":"Akush Ginekol"},{"issue":"9","key":"995_CR76","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/j.1471-0528.2006.01041.x","volume":"113","author":"S Georgala","year":"2006","unstructured":"Georgala S, Katoulis A, Befon A, Georgala C, Rigopoulos D. Short communication: oral inosiplex in the treatment of cervical condylomata acuminata: a randomised placebo-controlled trial. BJOG. 2006;113(9):1088\u201391. https:\/\/doi.org\/10.1111\/j.1471-0528.2006.01041.x .","journal-title":"BJOG"},{"issue":"4","key":"995_CR77","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1054\/ijom.2001.0066","volume":"30","author":"F Femiano","year":"2001","unstructured":"Femiano F, Gombos F, Scully C. Oral proliferative verrucous leukoplakia (PVL); open trial of surgery compared with combined therapy using surgery and methisoprinol in papillomavirus-related PVL. Int J Oral Maxillofac Surg. 2001;30(4):318\u201322. https:\/\/doi.org\/10.1054\/ijom.2001.0066 .","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"4","key":"995_CR78","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1128\/AAC.5.4.403","volume":"5","author":"DM Pachuta","year":"1974","unstructured":"Pachuta DM, Togo Y, Hornick RB, Schwarts AR, Tominaga S. Evaluation of isoprinosine in experimental human rhinovirus infection. Antimicrob Agents Chemother. 1974;5(4):403\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"995_CR79","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1749-6632.1977.tb21946.x","volume":"284","author":"RH Waldman","year":"1977","unstructured":"Waldman RH, Ganguly R. Therapeutic efficacy of inosiplex (Isoprinosine\u00ae) in rhinovirus infection. Ann N Y Acad Sci. 1977;284(1):153\u201360.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"995_CR80","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/jac\/7.4.389","volume":"7","author":"RA Khakoo","year":"1981","unstructured":"Khakoo RA, Watson GW, Waldman RH, Ganguly R. Effect of inosiplex (isoprinosine) on induced human influenza A infection. J Antimicrob Chemother. 1981;7(4):389\u201397.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"995_CR81","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1186\/s12879-016-1965-5","volume":"16","author":"J Beran","year":"2016","unstructured":"Beran J, \u0160alapov\u00e1 E, \u0160pajdel M. Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a phase 4, randomised, placebo-controlled, double-blind study. BMC Infect Dis. 2016;16(1):648.","journal-title":"BMC Infect Dis"},{"issue":"10","key":"995_CR82","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/BF01072462","volume":"23","author":"KC Lam","year":"1978","unstructured":"Lam KC, Lin HJ, Lai CL, Lam SK, Kwan YL. Isoprinosine in classical acute viral hepatitis. Am J Dig Dis. 1978;23(10):893\u20136.","journal-title":"Am J Dig Dis"},{"issue":"3","key":"995_CR83","first-page":"423","volume":"34","author":"A Scasso","year":"1983","unstructured":"Scasso A, Paladini A, Della Santa M. Methisoprinol in the treatment of acute B viral hepatitis: controlled clinical study. BMC Infect Dis. 1983;34(3):423\u201335.","journal-title":"BMC Infect Dis"},{"key":"995_CR84","doi-asserted-by":"publisher","first-page":"35","DOI":"10.18044\/medinform.201411.35","volume":"1","author":"N Nikolova","year":"2014","unstructured":"Nikolova N, Antonov K, Mateva L. Krastev Z Could Inosine pranobex and ribavirin in combination restore immune competence in chronic HCV advanced liver disease? MedInform. 2014;1:35\u201344. https:\/\/doi.org\/10.18044\/medinform.201411.35 .","journal-title":"MedInform"},{"issue":"2","key":"995_CR85","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/S0168-8278(05)80410-6","volume":"21","author":"M Pardo","year":"1994","unstructured":"Pardo M, Carre\u00f1o V. Lack of efficacy of inosine pranobex in the treatment of chronic hepatitis C. J Hepatol. 1994;21(2):278.","journal-title":"J Hepatol"},{"issue":"1","key":"995_CR86","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0090-1229(86)90218-7","volume":"39","author":"JI Wallace","year":"1986","unstructured":"Wallace JI, Bekesi JG. A double-blind clinical trial of the effects of inosine pranobex in immunodepressed patients with prolonged generalized lymphadenopathy. Clin Immunol Immunopathol. 1986;39(1):179\u201386.","journal-title":"Clin Immunol Immunopathol"},{"issue":"25","key":"995_CR87","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1056\/nejm199006213222501","volume":"322","author":"C Pedersen","year":"1990","unstructured":"Pedersen C, Sandstr\u00f6m E, Petersen CS, Norkrans G, Gerstoft J, Karlsson A, et al. the efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. N Engl J Med. 1990;322(25):1757\u201363. https:\/\/doi.org\/10.1056\/nejm199006213222501 .","journal-title":"N Engl J Med"},{"issue":"6","key":"995_CR88","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1128\/AAC.37.6.1227","volume":"37","author":"JA Kovacs","year":"1993","unstructured":"Kovacs JA, Powell F, Voeller D, Allegra CJ. Inhibition of Pneumocystis carinii dihydropteroate synthetase by para-acetamidobenzoic acid: possible mechanism of action of isoprinosine in human immunodeficiency virus infection. Antimicrob Agents Chemother. 1993;37(6):1227\u201331.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"995_CR89","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0192-0561(91)90120-V","volume":"13","author":"C De Simone","year":"1991","unstructured":"De Simone C, Famularo G, Tzantzoglou S, Moretti S, Jirillo E. Inosine pranobex in the treatment of HIV infection: a review. Int J Immunopharmacol. 1991;13(Suppl 1):19\u201327.","journal-title":"Int J Immunopharmacol"},{"issue":"5","key":"995_CR90","doi-asserted-by":"publisher","first-page":"422","DOI":"10.2340\/00015555-0138","volume":"86","author":"S Georgala","year":"2006","unstructured":"Georgala S, Katoulis AC, Befon A, Georgala K, Stavropoulos PG. Inosiplex for treatment of alopecia areata: a randomized placebo-controlled study. Acta Derm Venereol. 2006;86(5):422\u20134.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"995_CR91","first-page":"643","volume":"8","author":"J Wybran","year":"1981","unstructured":"Wybran J, Famaey JP, Appelboom T. Inosiplex: a novel treatment in rheumatoid arthritis? J Rheumatol. 1981;8(4):643\u20136.","journal-title":"J Rheumatol"},{"issue":"2","key":"995_CR92","first-page":"113","volume":"47","author":"M Sadowska-Wroblewska","year":"1988","unstructured":"Sadowska-Wroblewska M, Wroblewska-Graff T, Werynska-Przybylska J, Rell-Bakalarska M, Kurdybacha J. Isoprinosine in the early pre-erosive stage of rheumatoid arthritis: a pilot study. Z Rheumatol. 1988;47(2):113\u20136.","journal-title":"Z Rheumatol"},{"issue":"3","key":"995_CR93","first-page":"93","volume":"14","author":"H Becker","year":"1986","unstructured":"Becker H, Loers E, Helmke K, Federlin K. Therapy of rheumatic diseases with inosiplex. Immun Infekt. 1986;14(3):93\u20139.","journal-title":"Immun Infekt"},{"key":"995_CR94","unstructured":"Centers for disease control and prevention. What is ME\/CFS? 2018. https:\/\/www.cdc.gov\/me-cfs\/about\/index.html . Accessed 15 Feb 2019."},{"key":"995_CR95","volume-title":"Atlas: multiple sclerosis resources in the world 2008","author":"World Health Organization","year":"2008","unstructured":"World Health Organization. Atlas: multiple sclerosis resources in the world 2008. Geneva: World Health Organization; 2008."},{"key":"995_CR96","doi-asserted-by":"publisher","DOI":"10.1007\/978-88-470-2117-4","volume-title":"Early indicators early treatments neuroprotection in multiple sclerosis","author":"OR Hommes","year":"2004","unstructured":"Hommes OR, Comi G. Early indicators early treatments neuroprotection in multiple sclerosis. Milano: Springer; 2004."},{"issue":"4","key":"995_CR97","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1600-0404.1986.tb03517.x","volume":"74","author":"C Caltagirone","year":"1986","unstructured":"Caltagirone C, Carlesimo A. Methisoprinol in the treatment of multiple sclerosis. A pilot study. Acta Neurol Scand. 1986;74(4):293\u20136.","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"995_CR98","first-page":"175","volume":"131","author":"P Mazzarello","year":"1982","unstructured":"Mazzarello P, Rocchelli B, Poloni M, Delodovici M, Pinelli P. Isoprinosine in multiple sclerosis treatment: a preliminary study. Schweiz Arch Neurol Neurochir Psychiatr. 1982;131(2):175\u20139.","journal-title":"Schweiz Arch Neurol Neurochir Psychiatr"},{"key":"995_CR99","first-page":"377","volume":"1","author":"A Pompidou","year":"1987","unstructured":"Pompidou A, Rancurel G, Delsaux M, Meunier C, Telvi L, Cour V, et al. Immunosuppressive effects of isoprinosine in man: a comparison to chlorambucil effects in multiple sclerosis. Cancer Detect Prev Suppl. 1987;1:377\u201383.","journal-title":"Cancer Detect Prev Suppl"},{"issue":"2","key":"995_CR100","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1136\/jnnp.57.2.164","volume":"57","author":"NM Milligan","year":"1994","unstructured":"Milligan NM, Miller DH, Compston DA. A placebo-controlled trial of isoprinosine in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 1994;57(2):164\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"995_CR101","unstructured":"World Health Organization. Global tuberculosis report 2018. 2018."},{"issue":"2","key":"995_CR102","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2174\/187152607781001817","volume":"7","author":"M Laurenzi","year":"2007","unstructured":"Laurenzi M, Ginsberg A, Spigelman M. Challenges associated with current and future TB treatment. Curr Drug Targets Infect Disord. 2007;7(2):105\u201319.","journal-title":"Curr Drug Targets Infect Disord"},{"key":"995_CR103","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mehy.2018.04.002","volume":"115","author":"AK Mishra","year":"2018","unstructured":"Mishra AK, Yabaji SM, Dubey RK. Evaluation of isoprinosine to be repurposed as an adjunct anti-tuberculosis chemotherapy. Med Hypotheses. 2018;115:77\u201380. https:\/\/doi.org\/10.1016\/j.mehy.2018.04.002 .","journal-title":"Med Hypotheses"},{"issue":"6","key":"995_CR104","doi-asserted-by":"publisher","first-page":"320","DOI":"10.14238\/pi53.6.2013.320-7","volume":"53","author":"MG Ompico","year":"2013","unstructured":"Ompico MG. Methisoprinol for children with early phase dengue infection: a pilot study. Paediatr Indones. 2013;53(6):320\u20137.","journal-title":"Paediatr Indones"},{"issue":"1","key":"995_CR105","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1128\/aac.36.1.191","volume":"36","author":"ME Sarciron","year":"1992","unstructured":"Sarciron ME, Delabre I, Walbaum S, Raynaud G, Petavy AF. Effects of multiple doses of isoprinosine on Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother. 1992;36(1):191\u20134. https:\/\/doi.org\/10.1128\/aac.36.1.191 .","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"995_CR106","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/bf00931540","volume":"81","author":"ME Sarciron","year":"1995","unstructured":"Sarciron ME, Walbaum S. Petavy AF Effects of Isoprinosine on Echinococcus multilocularis and E. granulosus metacestodes. Parasitol Res. 1995;81(4):329\u201333. https:\/\/doi.org\/10.1007\/bf00931540 .","journal-title":"Parasitol Res"},{"issue":"3","key":"995_CR107","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1079\/JOH200049","volume":"75","author":"P Lawton","year":"2001","unstructured":"Lawton P, Walchshofer N, Sarciron M. In vitro effects of isoprinosine and a dipeptide methyl ester on Echinococcus multilocularis protoscoleces. J Helminthol. 2001;75(3):251\u20137.","journal-title":"J Helminthol"},{"issue":"12","key":"995_CR108","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1177\/088307380301801201","volume":"18","author":"GG Gascon","year":"2003","unstructured":"Gascon GG. Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-\u03b1 in subacute sclerosing panencephalitis (SSPE): international multicenter study. J Child Neurol. 2003;18(12):819\u201327.","journal-title":"J Child Neurol"},{"issue":"1","key":"995_CR109","first-page":"67","volume":"52","author":"T Nakamura","year":"1983","unstructured":"Nakamura T, Miyasaka N, Pope RM, Talal N, Russell IJ. Immunomodulation by isoprinosine: effects on in vitro immune functions of lymphocytes from humans with autoimmune diseases. Clin Exp Immunol. 1983;52(1):67\u201374.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"995_CR110","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0192-0561(86)90074-3","volume":"8","author":"M Wiranowska-Stewart","year":"1986","unstructured":"Wiranowska-Stewart M, Hadden JW. Effects of isoprinosine and NPT 15392 on interleukin-2 (IL-2) production. Int J Immunopharmacol. 1986;8(1):63\u20139.","journal-title":"Int J Immunopharmacol"},{"issue":"4","key":"995_CR111","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/0192-0561(86)90129-3","volume":"8","author":"KY Tsang","year":"1986","unstructured":"Tsang KY, Donnelly R, Galbraith G, Fudenberg HH. Isoprinosine effects on interleukin-1 production in acquired immune deficiency syndrome (AIDS). Int J Immunopharmacol. 1986;8(4):437\u201341.","journal-title":"Int J Immunopharmacol"},{"issue":"5","key":"995_CR112","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1172\/JCI111858","volume":"75","author":"KY Tsang","year":"1985","unstructured":"Tsang KY, Fudenberg H, Galbraith G, Donnelly R, Bishop L, Koopmann W. Partial restoration of impaired interleukin-2 production and Tac antigen (putative interleukin-2 receptor) expression in patients with acquired immune deficiency syndrome by isoprinosine treatment in vitro. J Clin Invest. 1985;75(5):1538\u201344.","journal-title":"J Clin Invest"},{"issue":"3","key":"995_CR113","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1159\/000184362","volume":"46","author":"S Silvennoinen-Kassinen","year":"1987","unstructured":"Silvennoinen-Kassinen S, Karttunen R, Tiilikainen A, Huttunen K. Isoprinosine enhances PHA responses and has potential effect on natural killer cell (NK) activity of uremic patients in vitro. Nephron. 1987;46(3):243\u20136. https:\/\/doi.org\/10.1159\/000184362 .","journal-title":"Nephron"},{"issue":"4","key":"995_CR114","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/0192-0561(84)90049-3","volume":"6","author":"P Hersey","year":"1984","unstructured":"Hersey P, Bindon C, Bradley M, Hasic E. Effect of isoprinosine on interleukin 1 and 2 production and on suppressor cell activity in pokeweed mitogen stimulated cultures of B and T cells. Int J Immunopharmacol. 1984;6(4):321\u20138.","journal-title":"Int J Immunopharmacol"},{"key":"995_CR115","first-page":"116","volume":"23","author":"C De Simone","year":"1981","unstructured":"De Simone C, Capozzi C, Campo S, Ricca D, Matteucci G. Effect of azathioprine and inosiplex on rosette formation by lymphocytes from normal donors and from patients with neoplasia. Ann Sclavo. 1981;23:116\u201324.","journal-title":"Ann Sclavo"},{"issue":"8293","key":"995_CR116","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(82)90300-2","volume":"320","author":"M Galli","year":"1982","unstructured":"Galli M, Lazzarin A, Moroni M, Zanussi C. Inosiplex in recurrent herpes simplex infections. Lancet. 1982;320(8293):331\u20132.","journal-title":"Lancet"},{"key":"995_CR117","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/978-1-4615-9358-4_27","volume-title":"Immunomodulation: new frontiers and advances","author":"M Galli","year":"1984","unstructured":"Galli M, Lazzarin A, Moroni M, Zanussi C. Treatment of recurrent viral infectious diseases by methisoprinol. In: Fudenberg HH, Whitten HD, Ambrogi F, editors. Immunomodulation: new frontiers and advances. Boston: Springer; 1984. p. 385\u201397."},{"issue":"8433","key":"995_CR118","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S0140-6736(85)92239-1","volume":"325","author":"DJ Talbot","year":"1985","unstructured":"Talbot DJ, Menday AP, Saurat JH. Inosine pranobex in mucocutaneous herpes. Lancet. 1985;325(8433):877. https:\/\/doi.org\/10.1016\/S0140-6736(85)92239-1 .","journal-title":"Lancet"},{"key":"995_CR119","volume-title":"The successful treatment of Herpes genitalis with Imunovir (inosine pranobex) 6th International Meeting of the International Society for STD Research; 31st July\u20132nd August 1985","author":"J Cutler","year":"1985","unstructured":"Cutler J, Talbot DJ. The successful treatment of Herpes genitalis with Imunovir (inosine pranobex) 6th International Meeting of the International Society for STD Research; 31st July\u20132nd August 1985. England: Brighton; 1985."},{"issue":"4","key":"995_CR120","first-page":"681","volume":"43","author":"M Byrne","year":"1988","unstructured":"Byrne M, Lawrence A, Walker G, O\u2019Neill O, Csonka G, John J. Suppression of recurrent genital herpes by inosine pranobex: effects of episodic and continuous treatment. BMC Infect Dis. 1988;43(4):681\u20138.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"995_CR121","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1136\/sti.65.2.103","volume":"65","author":"A Mindel","year":"1989","unstructured":"Mindel A, Carney O, Sonnex C, Freris M, Patou G, Williams P. Suppression of frequently recurring genital herpes: acyclovir v inosine pranobex. Sex Transm Infect. 1989;65(2):103\u20135.","journal-title":"Sex Transm Infect"},{"issue":"5","key":"995_CR122","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/sti.68.5.312","volume":"68","author":"G Kinghorn","year":"1992","unstructured":"Kinghorn G, Woolley P, Thin R, De Maubeuge J, Foidart J-M, Engst R. Acyclovir vs. isoprinosine (immunovir) for suppression of recurrent genital herpes simplex infection. Sex Transm Infect. 1992;68(5):312\u20136.","journal-title":"Sex Transm Infect"},{"issue":"3","key":"995_CR123","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1128\/AAC.14.3.495","volume":"14","author":"S Feldman","year":"1978","unstructured":"Feldman S, Hayes FA, Chaudhary S, Ossi M. Inosiplex for localized herpes zoster in childhood cancer patients: preliminary controlled study. Antimicrob Agents Chemother. 1978;14(3):495\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"995_CR124","first-page":"191","volume":"11","author":"B Lesourd","year":"1982","unstructured":"Lesourd B, Laude J, Meunier P, Doumerc S, Moulias R. Isoprinosine treatment of herpes zoster. Results of a control study in 36 subjects. Nouv Presse Med. 1982;11(3):191\u20133.","journal-title":"Nouv Presse Med"},{"issue":"10","key":"995_CR125","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/0031-6989(86)90101-3","volume":"18","author":"M Castelli","year":"1986","unstructured":"Castelli M, Zanca A, Giubertoni G, Zanca A, Bertolini A. Griseofulvin-methisoprinol combination in the treatment of herpes zoster. Pharmacol Res Commun. 1986;18(10):991\u20136.","journal-title":"Pharmacol Res Commun"},{"issue":"1","key":"995_CR126","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3109\/00365548909035675","volume":"21","author":"CMR Payne","year":"1989","unstructured":"Payne CMR, Menday AP, Rogers T, Staughton RC. Isoprinosine does not influence the natural history of herpes zoster or postherpetic neuralgia. Scand J Infect Dis. 1989;21(1):15\u20138.","journal-title":"Scand J Infect Dis"},{"issue":"3 Pt 1","key":"995_CR127","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1212\/WNL.42.3.488","volume":"42","author":"K Yalaz","year":"1992","unstructured":"Yalaz K, Anlar B, Oktem F, Aysun S, Ustacelebi S, Gurcay O, et al. Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis. Neurology. 1992;42(3 Pt 1):488\u201391.","journal-title":"Neurology"},{"issue":"5","key":"995_CR128","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/0387-7604(93)90120-W","volume":"15","author":"G Gascon","year":"1993","unstructured":"Gascon G, Yamani S, Crowell J, Stigsby B, Nester M, Kanaan I, et al. Combined oral isoprinosine-intraventricular alpha-interferon therapy for subacute sclerosing panencephalitis. Brain Dev. 1993;15(5):346\u201355.","journal-title":"Brain Dev"},{"issue":"2","key":"995_CR129","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1212\/WNL.48.2.526","volume":"48","author":"B Anlar","year":"1997","unstructured":"Anlar B, Yalaz K, Oktem F, Kose G. Long-term follow-up of patients with subacute sclerosing panencephalitis treated with intraventricular alpha-interferon. Neurology. 1997;48(2):526\u20138.","journal-title":"Neurology"},{"issue":"1","key":"995_CR130","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S0022-510X(98)00302-5","volume":"162","author":"Z Gokcil","year":"1999","unstructured":"Gokcil Z, Odabasi Z, Demirkaya S, Eroglu E, Vural O. Alpha-interferon and isoprinosine in adult-onset subacute sclerosing panencephalitis. J Neurol Sci. 1999;162(1):62\u20134.","journal-title":"J Neurol Sci"},{"issue":"1\u20132","key":"995_CR131","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jns.2008.07.033","volume":"275","author":"E Eroglu","year":"2008","unstructured":"Eroglu E, Gokcil Z, Bek S, Ulas UH, Ozdag MF, Odabasi Z. Long-term follow-up of patients with adult-onset subacute sclerosing panencephalitis. J Neurol Sci. 2008;275(1\u20132):113\u20136.","journal-title":"J Neurol Sci"},{"key":"995_CR132","first-page":"3","volume":"21","author":"G Zagni","year":"1982","unstructured":"Zagni G, Cannarozzo C. Clinical trial on the topical application of methisoprinol in some cutaneous viruses. Clin Eur. 1982;21:3\u20137.","journal-title":"Clin Eur"},{"issue":"5","key":"995_CR133","first-page":"415","volume":"34","author":"J Malgouyat","year":"1983","unstructured":"Malgouyat J. A new approach to the treatment of genital condyloma in women. Gynecologie. 1983;34(5):415\u2013517.","journal-title":"Gynecologie"},{"issue":"2","key":"995_CR134","first-page":"101","volume":"19","author":"M Mihula","year":"2015","unstructured":"Mihula M. Possible treatment of anogenital warts with the immunomodulation agent Isoprinosine. Prakt Gyn. 2015;19(2):101\u20136.","journal-title":"Prakt Gyn"},{"key":"995_CR135","first-page":"39","volume":"2","author":"B Nejmark","year":"2015","unstructured":"Nejmark B, Kondrat\u2019eva J, Zologina V, Torbik D. Effectiveness of combined treatment of HPV infection. Urologiia. 2015;2:39\u201340.","journal-title":"Urologiia"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00995-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-00995-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00995-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T02:00:45Z","timestamp":1721354445000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-00995-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,5]]},"references-count":135,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["995"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-00995-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,5]]},"assertion":[{"value":"6 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}